Ignite Creation Date:
2025-12-25 @ 2:53 AM
Ignite Modification Date:
2026-04-20 @ 7:00 PM
Study NCT ID:
NCT04566133
Status:
TERMINATED
Last Update Posted:
2023-08-21
First Post:
2020-09-25
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Sponsor:
National Cancer Institute (NCI)
Organization:
Organization Data
Organization:
Class:
NIH
Study ID:
200152
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
NIH
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None